Allspring Global Investments Holdings LLC increased its holdings in Crystal Biotech Inc. (NASDAQ:KRYS – Free Report ) by 167.1% during the first quarter, according to the latest Form 13F filing with the Securities and Exchange Commission. The fund bought an additional 99,101 shares during the quarter, giving it a holding of 158,425 shares of the company. Allspring Global Investments Holdings LLC holds approximately 0.56% of Crystal Biotech Inc. shares, valued at $28,189,000, according to the latest filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently increased or decreased their investments in the company. Northern Trust Corporation increased its holdings in shares of Crystal Biotech by 2.0% in the third quarter. Northern Trust Corporation now owns 213,263 shares of the company’s stock valued at $24,739,000 after purchasing an additional 4,129 shares in the last quarter. Times Square Capital Management LLC purchased a new stake in Crystal Biotech in the third quarter valued at approximately $14,272,000. Graham Capital Management LP purchased a new stake in Crystal Biotech in the third quarter valued at approximately $330,000. Vanguard Group Inc. increased its holdings in shares of Crystal Biotech by 40.7% in the third quarter. Vanguard Group now owns 2,400,142 shares of the company’s stock, valued at $278,416,000, after purchasing an additional 693,852 shares in the last quarter. Finally, China Universal Asset Management increased its holdings in Crystal Biotech by 353.9% in the fourth quarter. China Universal Asset Management now owns 3,259 shares of the company’s stock, valued at $404,000, after purchasing an additional 2,541 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.
Insider Trading at Crystal Biotech
In other Crystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the Securities and Exchange Commission, which can be accessed on the SEC’s website. In related news, Director Julian S. Gangoli sold 20,000 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $164.13, for a total value of $3,282,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Additionally, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following this transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.
Analyst upgrades and downgrades
KRYS has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a target price of $200.00 on shares of Krystal Biotech in a research note on Monday, May 6th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Krystal Biotech and set a target price of $204.00 (up from the previous $178.00) in a report on Tuesday, April 16th. Nine research analysts have rated the stock with a buy rating. According to MarketBeat, the company has an average rating of “buy” and an average target price of $177.63.
Read our latest analysis on Crystal Biotech
Crystal Biotech stock price performance
Crystal Biotech’s shares opened trading at $184.34 on Friday. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 98.58 and a beta of 0.84. Crystal Biotech’s 52-week low is $93.95 and its 52-week high is $191.78. The stock’s 50-day moving average is $168.22 and its 200-day moving average is $152.31.
Krystal Biotech (NASDAQ:KRYS – Get free report ) last released its earnings results on Monday, May 6th. The company reported quarterly earnings per share of $0.03, missing the consensus estimate of $0.20 by ($0.17). The company’s quarterly revenue was $45.25 million, missing the consensus estimate of $47.37 million. The company’s revenue grew 452,400.0% year-over-year. Year-over-year earnings per share were ($1.76). Sell-side analysts expect that Krystal Biotech, Inc. will post 2.06 EPS for the current fiscal year.
Crystal Biotech Profile
(Free report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the U.S. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
References
Receive Krystal Biotech Daily News and Reviews –Enter your email address below to receive a concise summary of the latest news and analyst ratings on Krystal Biotech and related companies every day via MarketBeat.com’s free email newsletter.
